On March 13, 2023 Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab reported the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program (Press release, Genmab, MAR 13, 2023, View Source [SID1234628568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The share buy-back program is expected to be completed no later than March 31, 2023 and comprises up to 220,000 shares.

The following transactions were executed under the program from March 6, 2023, to March 10, 2023:

No. of shares Average price (DKK) Total value (DKK)
Accumulated through last announcement 78,000 204,581,960
March 06, 2023 12,000 2,560.23 30,722,760
March 07, 2023 10,000 2,541.68 25,416,800
March 08,2023 10,000 2,497.98 24,979,800
March 09, 2023 11,000 2,503.10 27,534,100
March 10, 2023 12,000 2,468.01 29,616,120

Total 55,000 138,269,580
Accumulated under the program 133,000 342,851,540
Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 676,416 shares as treasury shares, corresponding to 1.03% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation." Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 22, 2023.